A Neurologist’s Guide to Acute Migraine Therapy in the Emergency Room

The Neurohospitalist

Volumn 2, Issue 2, 2012, Pages 51-59

  Gelfand, Amy A ^a   Goadsby, Peter J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

headache; migraine disorders; primary headache disorders; quality

Indexed keywords

EID: 84992784676     PISSN: 19418744     EISSN: 19418752     Source Type: Journal    
DOI: 10.1177/1941874412439583     Document Type: Review

References (106)

1. Friedman BW Hochberg ML Esses D, et al. Applying the international classification of headache disorders to the emergency department: an assessment of reproducibility and the frequency with which a unique diagnosis can be assigned to every acute headache presentation. Ann Emerg Med. 2007; 49(4):409–419, 419 e401-409.
2. Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med. 2002; 39(3):215–222.
3. Rothrock JF. Images from headache: a costly attack of migraine. Headache. 2008; 48(6):951.
4. Ginder S Oatman B Pollack M. A prospective study of i.v. magnesium and i.v. prochlorperazine in the treatment of headaches. J Emerg Med. 2000; 18(3):311–315.
5. Cameron JD Lane PL Speechley M. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Acad Emerg Med. 1995; 2(7):597–602.
6. Miner JR Fish SJ Smith SW Biros MH. Droperidol vs. prochlorperazine for benign headaches in the emergency department. Acad Emerg Med. 2001; 8(9):873–879.
7. Shrestha M Singh R Moreden J Hayes JE. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern Med. 1996; 156(15):1725–1728.
8. Lane PL McLellan BA Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med. 1989; 18(4):360–365.
9. Goadsby PJ. The ‘Act when Mild’ (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia. 2008; 28(suppl 2):36–41.
10. Goadsby PJ Zanchin G Geraud G, et al. Early vs. non-early intervention in acute migraine-’Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008; 28(4):383–391.
11. Trottier ED Bailey B Lucas N Lortie A. Prochlorperazine in children with migraine: a look at its effectiveness and rate of akathisia. Am J Emerg Med. 22011 Feb 4 (Epub ahead of print).
12. Friedman BW Esses D Solorzano C, et al. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med. 2008; 52(4):399–406.
13. Shahien R Saleh SA Bowirrat A. Intravenous sodium valproate aborts migraine headaches rapidly. Acta Neurol Scand. 2011; 123(4):257–265.
14. Edwards KR Norton J Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001; 41(10):976–980.
15. Giffin NJ Ruggiero L Lipton RB, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology. 2003; 60(6):935–940.
16. Loga P Lewis D. Compazine in migraine. Emergency Medicine Journal (BMJ). 2007; 24(4):297–298.
17. Bell R Montoya D Shuaib A Lee MA. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med. 1990; 19(10):1079–1082.
18. Bigal ME Bordini CA Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002; 23(2):141–148.
19. Kelly AM Ardagh M Curry C D’Antonio J Zebic S. Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine. J Accid Emerg Med. 1997; 14(4):209–211.
20. Kostic MA Gutierrez FJ Rieg TS Moore TS Gendron RT. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med. 2010; 56(1):1–6.
21. Saadah HA. Abortive migraine therapy in the office with dexamethasone and prochlorperazine. Headache. 1994; 34(6):366–370.
22. Rozen TD. Acute therapy for migraine headaches. Semin Neurol. 2006; 26(2):181–187.
23. Leong LB Kelly AM. Are butyrophenones effective for the treatment of primary headache in the emergency department? CJEM. 2011; 13(2):96–104.
24. Ho TW Rodgers A Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009; 49(3):395–403.
25. Bigal ME Rapoport AM Lipton RB Tepper SJ Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003; 43(4):336–342.
26. Silberstein SD Olesen J Bousser MG, et al. The international classification of headache disorders, 2nd Edition (ICHD-II)—revision of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2005; 25(6):460–465.
27. Dodick D Freitag F. Evidence-based understanding of medication-overuse headache: clinical implications. Headache. 2006; 46(suppl 4):S202–S211.
28. Colman I Rothney A Wright SC Zilkalns B Rowe BH. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology. 2004; 62(10):1695–1700.
29. Buse DC Pearlman SH Serrano D Ng-Mak DS Reed ML Lipton RB. Rates of opioid use and dependence by sociodemographics, medical and psychiatric comorbidities, and headache-related disability among persons with Episodic Migraine (EM) in the US population: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2011; 51: 48.
30. Evans RW Friedman BW. Headache in the emergency department. Headache. 2011; 51(8):1276–1278.
31. Goadsby PJ Goldberg J Silberstein SD. Migraine in pregnancy. BMJ. 2008; 336(7659):1502–1504.
32. Charbit AR Akerman S Goadsby PJ. Dopamine: what’s new in migraine? Curr Opin Neurol. 2010; 23(3):275–281.
33. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004; 24(suppl 1):9–160.
34. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology. 2000; 55(6):754–762.
35. Jones J Pack S Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Am J Emerg Med. 1996; 14(3):262–264.
36. Miller MA Levsky ME Enslow W Rosin A. Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache. Am J Emerg Med. 2009; 27(2):160–164.
37. Coppola M Yealy DM Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995; 26(5):541–546.
38. McEwen JI O’Connor HM Dinsdale HB. Treatment of migraine with intramuscular chlorpromazine. Ann Emerg Med. 1987; 16(7):758–763.
39. Seim MB March JA Dunn KA. Intravenous ketorolac vs intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med. 1998; 5(6):573–576.
40. Jones EB Gonzalez ER Boggs JG Grillo JA Elswick RK Jr. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994; 24(2):237–241.
41. Jones J Sklar D Dougherty J White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA. 1989; 261(8):1174–1176.
42. Trottier ED Bailey B Dauphin-Pierre S Gravel J. Clinical outcomes of children treated with intravenous prochlorperazine for migraine in a pediatric emergency department. J Emerg Med. 2010; 39(2):166–173.
43. Tanen DA Miller S French T Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003; 41(6):847–853.
44. Scherl ER Wilson JF. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache. 1995; 35(5):256–259.
45. Davis CP Torre PR Williams C, et al. Ketorolac versus meperidine-plus-promethazine treatment of migraine headache: evaluations by patients. Am J Emerg Med. 1995; 13(2):146–150.
46. Information FPDS. http://www.fda.gov/Drugs/DrugSafetyPostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm182169.htm.
47. Weaver CS Jones JB Chisholm CD, et al. Droperidol vs prochlorperazine for the treatment of acute headache. J Emerg Med. 2004; 26(2):145–150.
48. Honkaniemi J Liimatainen S Rainesalo S Sulavuori S. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache. 2006; 46(5):781–787.
49. Salazar G Fragoso M Vergez L Sergio P Cuello D. Metoclopramide as an analgesic in severe migraine attacks: an open, single-blind, parallel control study. Recent Pat CNS Drug Discov. 2011; 6(2):141–145.
50. Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG study group. Cephalalgia. 1999; 19(6):581–588; discussion 542.
51. Akpunonu BE Mutgi AB Federman DJ, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med. 1995; 25(4):464–469.
52. Meredith JT Wait S Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003; 21(3):173–175.
53. Brandes JL Kudrow D Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007; 297(13):1443–1454.
54. Ferrari MD Roon KI Lipton RB Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001; 358(9294):1668–1675.
55. Diener HC Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs. 2001; 10(10):1831–1845.
56. Evans RW Tepper SJ Shapiro RE Sun-Edelstein C Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American headache society position paper. Headache. 2010; 50(6):1089–1099.
57. Hoskin KL Kaube H Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain. 1996; 119 (pt 1):249–256.
58. Callaham M Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986; 26(4):168–171.
59. Winner P Dalessio D Mathew N, et al. Office-based treatment of acute migraine with dihydroergotamine mesylate. Headache. 1993; 33(9):471–475.
60. Tepper SJ Kori SH Goadsby PJ, et al. MAP0004, Orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc. 2011; 86(10):948–955.
61. Becker WJ Riess CM Hoag J. Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache. 1996; 36(3):144–148.
62. Monteith TS Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Curr Treat Options Neurol. 2011; 13(1):1–14.
63. Saper JR Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006; 46(suppl 4):S171–S181.
64. Morren JA Galvez-Jimenez N. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy? Expert Opin Pharmacother. 2010; 11(18):3085–3093.
65. Nagy A Gandi S Bhola R Goadsby PJ. Intravenous dihydroergotamine (DHE) for inpatient management of refractory primary headaches. Neurology. 2011; 77(20):1827–1832.
66. Gray RN McCrory DC Eberlein K Westman EC Hasselblad V. 1999.
67. Leniger T Pageler L Stude P Diener HC Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache. 2005; 45(1):42–46.
68. Weatherall MW Telzerow AJ Cittadini E Kaube H Goadsby PJ. Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache. Neurology. 2010; 75(12):1098–1103.
69. Arora S Wagner JG Herbert M. Myth: parenteral ketorolac provides more effective analgesia than oral ibuprofen. CJEM. 2007; 9(1):30–32.
70. Engindeniz Z Demircan C Karli N, et al. Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: a prospective, randomised, double-blind study. J Headache Pain. 2005; 6(3):143–148.
71. Freitag FG Collins SD Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002; 58(11):1652–1659.
72. Thomaides T Karapanayiotides T Kerezoudi E, et al. Intravenous valproate aborts glyceryl trinitrate-induced migraine attacks: a clinical and quantitative EEG study. Cephalalgia. 2008; 28(3):250–256.
73. Loscher W Vetter M. In vivo effects of aminooxyacetic acid and valproic acid on nerve terminal (synaptosomal) GABA levels in discrete brain areas of the rat. Correlation to pharmacological activities. Biochem Pharmacol. 1985; 34(10):1747–1756.
74. Cutrer FM Moskowitz MA. Wolff award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache. 1996; 36(10):579–585.
75. Cutrer FM Limmroth V Ayata G Moskowitz MA. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol. 1995; 116(8):3199–3204.
76. Hering R Steiner TJ. Sodium valproate for acute migraine attacks. Cephalalgia. 1994; 14(4):305–306.
77. Mathew NT Kailasam J Meadors L Chernyschev O Gentry P. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache. 2000; 40(9):720–723.
78. Segura-Bruna N Rodriguez-Campello A Puente V Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand. 2006; 114(1):1–7.
79. Anderton JM Helm R. Multiple joint osteonecrosis following short-term steroid therapy. Case report. J Bone Joint Surg Am. 1982; 64(1):139–141.
80. McCluskey J Gutteridge DH. Avascular necrosis of bone after high doses of dexamethasone during neurosurgery. Br Med J (Clin Res Ed). 1982; 284(6312):333–334.
81. Fast A Alon M Weiss S Zer-Aviv FR. Avascular necrosis of bone following short-term dexamethasone therapy for brain edema. Case report. J Neurosurg. 1984; 61(5):983–985.
82. Watkins S Williams JR. Avascular necrosis of bone after high doses of dexamethasone during neurosurgery. Br Med J (Clin Res Ed). 1982; 284(6317):742.
83. Stiller J. Management of acute intractable headaches using i. v. therapy in an office setting. Headache. 1992; 32(10):514–515.
84. Rowe BH Colman I Edmonds ML Blitz S Walker A Wiens S. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache. Headache. 2008; 48(3):333–340.
85. Donaldson D Sundermann R Jackson R Bastani A. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial. Am J Emerg Med. 2008; 26(2):124–130.
86. Kelly AM Kerr D Clooney M. Impact of oral dexamethasone versus placebo after ED treatment of migraine with phenothiazines on the rate of recurrent headache: a randomised controlled trial. Emerg Med J. 2008; 25(1):26–29.
87. Singh A Alter HJ Zaia B. Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department? A meta-analysis and systematic review of the literature. Acad Emerg Med. 2008; 15(12):1223–1233.
88. Colman I Friedman BW Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008; 336(7657):1359–1361.
89. Innes GD Macphail I Dillon EC Metcalfe C Gao M. Dexamethasone prevents relapse after emergency department treatment of acute migraine: a randomized clinical trial. CJEM. 1999; 1(1):26–33.
90. Friedman BW Greenwald P Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007; 69(22):2038–2044.
91. Legault G Eisman H Shevell MI. Treatment of pediatric status migrainosus: can we prevent the “bounce back”? J Child Neurol. 2011; 26(8):949–955.
92. Nappi G Sicuteri F Byrne M Roncolato M Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol. 1994; 241(3):138–144.
93. Friedman BW Solorzano C Esses D, et al. Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. Ann Emerg Med. 2010; 56(1):7–17.
94. Cady RK Rubino J Crummett D Littlejohn TW, 3rd. Oral sumatriptan in the treatment of recurrent headache. Arch Fam Med. 1994; 3(9):766–772.
95. Ferrari MD James MH Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994; 14(5):330–338.
96. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000; 58(2B):428–430.
97. Kabbouche MA Powers SW Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009; 49(1):106–109.
98. Lewis D Middlebrook MT Deline C. Naproxen sodium for chemophrophylaxis of adolescent migraine. Ann Neurol. 1994; 36: 542.
99. Bellavance AJ Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache. 1990; 30(11):710–715.
100. Welch KM Ellis DJ Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology. 1985; 35(9):1304–1310.
101. Sargent J Solbach P Damasio H, et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache. 1985; 25(6):320–324.
102. Ziegler DK Ellis DJ. Naproxen in prophylaxis of migraine. Arch Neurol. 1985; 42(6):582–584.
103. Bigal ME Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008; 71(22):1821–1828.
104. Glaxo Smith Kline Pregnancy Registries, Sumatriptan/Naratriptan/Treximet Pregnancy Registry, http://pregnancyregistry.gsk.com/sumatriptan.html; accessed Feb 19, 2012.
105. Goadsby PJ Yates R. Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Headache. 2006; 46: 138–149.
106. Baden EY Hunter CJ. Intravenous dexamethasone to prevent the recurrence of benign headache after discharge from the emergency department: a randomized, double-blind, placebo-controlled clinical trial. CJEM. Nov 2006; 8(6):393–400.